Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
NCT02348216
Completed
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6). The primary objectives of this study are: * Phase 1 Study: Evaluate the safety of axicabtagene ciloleucel regimens * Phase 2 Pivotal Study; Evaluate the efficacy of axicabtagene ciloleucel * Phase 2 Safety Management Study: Assess the impact of prophylactic regimens or earlier inte... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +35 locations
Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
Register for Updates
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967
Active Not Recruiting
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Southern Cancer Center PC-Mobile, Mobile, Alabama +1295 locations
Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Register for Updates
Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma
NCT00110110
Active Not Recruiting
RATIONALE: Drugs used in chemotherapy, such as carboplatin, etoposide, and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sometimes when chemotherapy is given, it does not stop the growth of tumor cells. The tumor is said to be resistant to chemotherapy. Giving cyclosporine together with chemotherapy may reduce drug resistance and allow the tumor cells to be killed. Cryotherapy kills tumor cells by freezing th... Read More
Gender:
ALL
Ages:
30 days and above
Trial Updated:
04/15/2024
Locations: Children's and Women's Hospital of British Columbia, Vancouver, British Columbia +5 locations
Conditions: Retinoblastoma
Register for Updates
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
NCT00653068
Completed
This phase III trial studies the side effects of combination chemotherapy, 3-dimensional conformal radiation therapy, and an autologous peripheral blood stem cell transplant, and to see how well they work in treating young patients with atypical teratoid/rhabdoid tumor of the central nervous system. Giving high-dose chemotherapy before an autologous peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating fac... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
04/03/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +93 locations
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor
Register for Updates
COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors
NCT03206021
Completed
Many pediatric brain and solid tumors have altered epigenetic landscapes, and altered DNA methylation. As such this study is a Phase I/Ib study of combined 5'Azacitidine with an escalating dose of carboplatin for all recurrent/refractory pediatric brain and solid tumors. The phase I component will establish with maximum tolerated dose of carboplatin with azacytidine. An expansion cohort will be recruited of up to 30 patients will follow consisting of 20 recurrent posterior fossa ependymoma and 1... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
04/03/2024
Locations: Children's National Medical Center, Washington, District of Columbia +16 locations
Conditions: Recurrent Childhood CNS Tumor, Ependymoma, Recurrent Childhood, Childhood Solid Tumor
Register for Updates
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
NCT06107868
Active Not Recruiting
This is a phase 1 study to evaluate investigational drug RP-6306 in combination with carboplatin and paclitaxel in patients with TP53 mutated ovarian or uterine cancer. The dose escalation part of the study will determine the maximum tolerated dose (MTD) and recommended Phase 2 Dose (RP2D) and schedule of RP-6306 in combination with carboplatin and paclitaxel and the dose expansion will further assess the safety and tolerability as well as determine the preliminary efficacy of RP-6306 in combina... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Princess Margaret Cancer Centre, Toronto, Ontario
Conditions: Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer, Advanced Cancer
Register for Updates
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
NCT02337530
Completed
The purpose of this study is to find out what effects a new drug, selumetinib, has on lung cancer when receiving standard chemotherapy with pemetrexed and platinum-based chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Tom Baker Cancer Centre, Calgary, Alberta +11 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
NCT04440358
Active Not Recruiting
The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/12/2024
Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario +2 locations
Conditions: Recurrent Glioblastoma
Register for Updates
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
NCT03840902
Terminated
The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: University of California Irvine Medical Center, Orange, California +103 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
NCT02684058
Completed
The purpose of this study was to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma (LGG) or relapsed or refractory high grade glioma (HGG)
Gender:
ALL
Ages:
Between 12 months and 17 years
Trial Updated:
11/20/2023
Locations: Children's Hospital of Orange County, Orange, California +56 locations
Conditions: Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma
Register for Updates
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
NCT04016389
Recruiting
This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment. Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior to surgery can maintain fertility in patients with invasive cervical cancer. The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy dru... Read More
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
11/03/2023
Locations: MD Anderson Cancer Centre, Houston, Texas +3 locations
Conditions: Cervical Cancer
Register for Updates
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02272790
Completed
Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
Gender:
FEMALE
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2023
Locations: Research Site, Gilbert, Arizona +19 locations
Conditions: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Register for Updates